{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"pt-141-cognition","title":"PT-141 for Cognition: Melanocortin Pathways, CNS Arousal, and the Evidence Base","body":"## What's breaking down\nCognition depends on coordinated brain networks for motivation, reward processing, attention, and memory consolidation. When these networks underperform, people often notice reduced drive to start tasks, flatter emotional tone during focused work, or weaker follow-through on learning. Melanocortin receptors (especially MC3R and MC4R) sit in hypothalamic and limbic areas that help regulate these functions. If signaling through these receptors is low, the excitatory push that normally supports motivated attention and reward-linked memory can weaken. PT-141 is a melanocortin agonist that crosses into central pathways; any discussion of its use for cognition starts from this shared biology rather than from a claim that it repairs structural damage or suppresses symptoms.\n\n## Why PT-141 might help you\n1. If your main issue is low motivational tone or reduced mental arousal when starting cognitively demanding work, PT-141 is discussed because it activates MC4R receptors that have been linked in animal models to increased dopamine release in reward circuits.\n2. If reward sensitivity feels blunted (tasks that used to feel engaging now feel neutral), the same central mechanism that improves sexual desire in human trials could theoretically extend to other appetitive behaviors, though this remains untested in cognition-specific studies.\n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. It acts on central melanocortin pathways rather than on peripheral blood flow or broad neurotransmitter suppression.\n\n## How these fit together\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\nThe single focus here is PT-141 acting on CNS arousal pathways that overlap with motivational aspects of cognition. No additional peptides are in scope, so synergy discussion is limited to how its central mechanism might interact with everyday behaviors that support cognition, such as consistent engagement with learning tasks.\n\n## What the evidence actually shows\nHuman data are confined to sexual desire outcomes. Two identical phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found that 1.75 mg subcutaneous bremelanotide taken as needed produced statistically significant increases in desire scores (FSFI desire domain) and reductions in distress (FSDS-DAO item 13) versus placebo after 24 weeks. These trials enrolled over 1,200 women and reported the effects as clinically meaningful for the sexual endpoint. No cognitive endpoints were measured. Preclinical work shows melanocortin agonists influence sexual behavior and some appetitive responses in rodents, but direct cognition assays (memory, executive function) are absent from published PT-141 studies. Anecdotal reports exist but are low-tier and tied to libido use rather than isolated cognitive testing.\n\n## What scientists say\nResearchers describe PT-141 as a selective melanocortin agonist that acts centrally to modulate excitatory pathways involved in sexual motivation. Reviews note that MC4R signaling can intersect with dopamine systems in the medial preoptic area and limbic regions, providing a mechanistic bridge to reward and drive. Scientists consistently state that any extension to non-sexual cognition is speculative; no dedicated human trials on memory, attention, or executive function have been published. One review highlights that melanocortins broadly influence energy balance, inflammation, and social behavior, yet cautions that receptor subtype distribution and downstream effects vary by brain region and remain incompletely mapped for cognitive domains.\n\n## What people say on Reddit\nUser reports on forums such as r/Biohackers and r/NTNPerformance describe PT-141 primarily in the context of libido and erections. A subset mention secondary feelings of increased well-being, reduced depressive tone, or heightened pleasure during activities, sometimes framed as “antidepressant-like.” These accounts are self-reported, lack controlled conditions or cognitive testing, and often combine PT-141 with other compounds. No consistent reports isolate improvements in focus, memory recall, or problem-solving speed. Tolerance concerns and the need for cycling appear repeatedly in anecdotal threads.\n\n## What people say on X\nPosts on X discussing PT-141 focus almost exclusively on sexual desire and arousal timing. Occasional mentions link the compound to broader “motivation” or “drive,” but these remain tied to libido experiences rather than objective cognitive metrics. No verified high-engagement threads present before-and-after cognitive testing or controlled observations.\n\n## What we do not know\nNo human trials have measured PT-141 effects on standardized cognitive batteries, working memory, processing speed, or attention tasks. It is unknown whether any motivational changes observed in sexual contexts generalize to non-sexual cognitive performance. Long-term effects on brain plasticity or neurodegeneration markers have not been studied. Dose-response relationships for any potential cognitive layer are undefined. Differences between subcutaneous FDA-approved use and research-grade or compounded versions remain uncharacterized for non-sexual outcomes.\n\n## Safety and limits\nThe most common side effects reported in the phase 3 HSDD trials were nausea, flushing, and headache, occurring in 10% or more of participants and leading to discontinuation in a minority. The compound is FDA-approved only for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Off-label exploration for cognition carries the standard risks of any unstudied indication, including unknown interactions and the absence of long-term safety data beyond sexual use. All claims remain graded by available evidence tiers; no cognitive benefit is established in humans.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-cognition/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Two phase 3 RCTs showed bremelanotide 1.75 mg SC improved sexual desire scores and reduced distress versus placebo in premenopausal women with HSDD.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the only robust human efficacy data for PT-141; confirms central mechanism but no cognitive endpoints measured.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"PT-141 acts as an agonist at MC3R and MC4R receptors expressed in the central nervous system.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the receptor-level basis for any discussion of CNS effects including possible motivational pathways.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No published human trials have assessed PT-141 on cognitive endpoints such as memory, attention, or executive function.","section":"What we do not know","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies the evidence gap for the article's specific topic.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Anecdotal Reddit reports describe secondary feelings of well-being or pleasure but do not isolate cognitive performance improvements.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents low-tier user observations without controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Phase 3 RCT results showing desire and distress improvements; no cognitive measures.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:18:54.082Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"2e68dd963d3bb9dbc811249c2ee9030d338819fd534e65c496d38645db60f7ed"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/12851303/","title":"PT-141: a melanocortin agonist for the treatment of sexual dysfunction","quote":"PT-141, a synthetic peptide analogue of alpha-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system.","summary":"Mechanism paper confirming receptor targets and CNS expression.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:18:54.082Z","link_status":"ok","quote_status":"verified","prev":"2e68dd963d3bb9dbc811249c2ee9030d338819fd534e65c496d38645db60f7ed","hash":"79f4cee5b28928ac0cb6b51a93bddf771f2dc889e751308b2cc7e5566b16ee36"},{"id":"s3","type":"other","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/","title":"Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder","quote":"The most common side effects of bremelanotide are nausea, vomiting, and flushing.","summary":"Review confirming trial focus remains sexual; no cognition data referenced.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:18:54.082Z","link_status":"ok","quote_status":"unverified","prev":"79f4cee5b28928ac0cb6b51a93bddf771f2dc889e751308b2cc7e5566b16ee36","hash":"f9b242c4b338f755dbcb6e284b5f6d2dcbd4143c8874c86a87d788036a5d2774"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1c39lie/pt_141_for_libido/","title":"PT 141 for libido","quote":"I have an increased sense of well-being, almost zero depression... increased pleasure (hedonic) beyond its effects used for ED.","summary":"User anecdote linking PT-141 to well-being but not to tested cognitive outcomes.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:18:54.082Z","link_status":"ok","quote_status":"unverified","prev":"f9b242c4b338f755dbcb6e284b5f6d2dcbd4143c8874c86a87d788036a5d2774","hash":"cadfae1aef2e6e5bee3467d30fdbe993c4f356d7f18d478dd74b2c993de97327"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:18:54.944Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for Cognition: Melanocortin Pathways, CNS Arousal, and the Evidence Base","register":"source_ledger","body":"## What's breaking down\nCognition depends on coordinated brain networks for motivation, reward processing, attention, and memory consolidation. When these networks underperform, people often notice reduced drive to start tasks, flatter emotional tone during focused work, or weaker follow-through on learning. Melanocortin receptors (especially MC3R and MC4R) sit in hypothalamic and limbic areas that help regulate these functions. If signaling through these receptors is low, the excitatory push that normally supports motivated attention and reward-linked memory can weaken. PT-141 is a melanocortin agonist that crosses into central pathways; any discussion of its use for cognition starts from this shared biology rather than from a claim that it repairs structural damage or suppresses symptoms.\n\n## Why PT-141 might help you\n1. If your main issue is low motivational tone or reduced mental arousal when starting cognitively demanding work, PT-141 is discussed because it activates MC4R receptors that have been linked in animal models to increased dopamine release in reward circuits.\n2. If reward sensitivity feels blunted (tasks that used to feel engaging now feel neutral), the same central mechanism that improves sexual desire in human trials could theoretically extend to other appetitive behaviors, though this remains untested in cognition-specific studies.\n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. It acts on central melanocortin pathways rather than on peripheral blood flow or broad neurotransmitter suppression.\n\n## How these fit together\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\nThe single focus here is PT-141 acting on CNS arousal pathways that overlap with motivational aspects of cognition. No additional peptides are in scope, so synergy discussion is limited to how its central mechanism might interact with everyday behaviors that support cognition, such as consistent engagement with learning tasks.\n\n## What the evidence actually shows\nHuman data are confined to sexual desire outcomes. Two identical phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found that 1.75 mg subcutaneous bremelanotide taken as needed produced statistically significant increases in desire scores (FSFI desire domain) and reductions in distress (FSDS-DAO item 13) versus placebo after 24 weeks. These trials enrolled over 1,200 women and reported the effects as clinically meaningful for the sexual endpoint. No cognitive endpoints were measured. Preclinical work shows melanocortin agonists influence sexual behavior and some appetitive responses in rodents, but direct cognition assays (memory, executive function) are absent from published PT-141 studies. Anecdotal reports exist but are low-tier and tied to libido use rather than isolated cognitive testing.\n\n## What scientists say\nResearchers describe PT-141 as a selective melanocortin agonist that acts centrally to modulate excitatory pathways involved in sexual motivation. Reviews note that MC4R signaling can intersect with dopamine systems in the medial preoptic area and limbic regions, providing a mechanistic bridge to reward and drive. Scientists consistently state that any extension to non-sexual cognition is speculative; no dedicated human trials on memory, attention, or executive function have been published. One review highlights that melanocortins broadly influence energy balance, inflammation, and social behavior, yet cautions that receptor subtype distribution and downstream effects vary by brain region and remain incompletely mapped for cognitive domains.\n\n## What people say on Reddit\nUser reports on forums such as r/Biohackers and r/NTNPerformance describe PT-141 primarily in the context of libido and erections. A subset mention secondary feelings of increased well-being, reduced depressive tone, or heightened pleasure during activities, sometimes framed as “antidepressant-like.” These accounts are self-reported, lack controlled conditions or cognitive testing, and often combine PT-141 with other compounds. No consistent reports isolate improvements in focus, memory recall, or problem-solving speed. Tolerance concerns and the need for cycling appear repeatedly in anecdotal threads.\n\n## What people say on X\nPosts on X discussing PT-141 focus almost exclusively on sexual desire and arousal timing. Occasional mentions link the compound to broader “motivation” or “drive,” but these remain tied to libido experiences rather than objective cognitive metrics. No verified high-engagement threads present before-and-after cognitive testing or controlled observations.\n\n## What we do not know\nNo human trials have measured PT-141 effects on standardized cognitive batteries, working memory, processing speed, or attention tasks. It is unknown whether any motivational changes observed in sexual contexts generalize to non-sexual cognitive performance. Long-term effects on brain plasticity or neurodegeneration markers have not been studied. Dose-response relationships for any potential cognitive layer are undefined. Differences between subcutaneous FDA-approved use and research-grade or compounded versions remain uncharacterized for non-sexual outcomes.\n\n## Safety and limits\nThe most common side effects reported in the phase 3 HSDD trials were nausea, flushing, and headache, occurring in 10% or more of participants and leading to discontinuation in a minority. The compound is FDA-approved only for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Off-label exploration for cognition carries the standard risks of any unstudied indication, including unknown interactions and the absence of long-term safety data beyond sexual use. All claims remain graded by available evidence tiers; no cognitive benefit is established in humans.","claims":[{"id":"c1","text":"Two phase 3 RCTs showed bremelanotide 1.75 mg SC improved sexual desire scores and reduced distress versus placebo in premenopausal women with HSDD.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the only robust human efficacy data for PT-141; confirms central mechanism but no cognitive endpoints measured.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"PT-141 acts as an agonist at MC3R and MC4R receptors expressed in the central nervous system.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the receptor-level basis for any discussion of CNS effects including possible motivational pathways.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No published human trials have assessed PT-141 on cognitive endpoints such as memory, attention, or executive function.","section":"What we do not know","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies the evidence gap for the article's specific topic.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Anecdotal Reddit reports describe secondary feelings of well-being or pleasure but do not isolate cognitive performance improvements.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents low-tier user observations without controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/12851303/","title":"PT-141: a melanocortin agonist for the treatment of sexual dysfunction","quote":"PT-141, a synthetic peptide analogue of alpha-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"other","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/","title":"Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder","quote":"The most common side effects of bremelanotide are nausea, vomiting, and flushing.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1c39lie/pt_141_for_libido/","title":"PT 141 for libido","quote":"I have an increased sense of well-being, almost zero depression... increased pleasure (hedonic) beyond its effects used for ED.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":15336,"tokens_out":3041,"cost":0.0267725,"prev_hash":"genesis","hash":"d5431a8e06f74a723b0250cce9c7b2f1e9af06d8043ea597f9e1e57c8f2f4c20"}],"provenance":[{"ts":"2026-06-30T01:18:54.944Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Cognition\nSlug: pt-141-cognition\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from pepti","response":"{\n  \"slug\": \"pt-141-cognition\",\n  \"title\": \"PT-141 for Cognition: Melanocortin Pathways, CNS Arousal, and the Evidence Base\",\n  \"body\": \"## What's breaking down\\nCognition depends on coordinated brain networks for motivation, reward processing, attention, and memory consolidation. When these networks underperform, people often notice reduced drive to start tasks, flatter emotional tone during focused work, or weaker follow-through on learning. Melanocortin receptors (especially MC3R and MC4R) sit in hypothalamic and limbic areas that help regulate these functions. If signaling through these receptors is low, the excitatory push that normally supports motivated attention and reward-linked memory can weaken. PT-141 is a melanocortin agonist that crosses into central pathways; any discussion of its use for cognition starts from this shared biology rather than from a claim that it repairs structural damage or suppresses symptoms.\\n\\n## Why PT-141 might help you\\n1. If your main issue is low motivational tone or reduced mental arousal when starting cognitively demanding work, PT-141 is discussed because it activates MC4R receptors that have been linked in animal models to increased dopamine release in reward circuits.\\n2. If reward sensitivity feels blunted (tasks that used to feel engaging now feel neutral), the same central mechanism that improves sexual desire in human trials could theoretically extend to other appetitive behaviors, though this remains untested in cognition-specific studies.\\n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. It acts on central melanocortin pathways rather than on peripheral blood flow or broad neurotransmitter suppression.\\n\\n## How these fit together\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\\nThe single","tokens_in":15336,"tokens_out":3041,"cost":0,"prev":"genesis","hash":"e11d402e2e64b5f9ee9aa02e01e4e3f08c763237c75967983523562e425ed068"},{"ts":"2026-07-17T02:41:04.978Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-cognition","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e11d402e2e64b5f9ee9aa02e01e4e3f08c763237c75967983523562e425ed068","hash":"a3e590b81a96aafbda5af36d20861058cea309ec1da2745fd9c976340b908905"}],"energy":{"passes":2,"tokens_in":15336,"tokens_out":3041,"tokens_total":18377,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"a3e590b81a96aafbda5af36d20861058cea309ec1da2745fd9c976340b908905"},"posted_at":"2026-06-29T21:32:52.033Z","created_at":"2026-06-29T21:32:52.033Z","updated_at":"2026-07-17T02:41:04.978Z","machine":{"shape":"article.machine/v1","slug":"pt-141-cognition","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-cognition","json":"https://miscsubjects.com/api/articles/pt-141-cognition","bundle":"https://miscsubjects.com/api/articles/pt-141-cognition/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-cognition/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-cognition","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-cognition\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-cognition\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-cognition/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-cognition\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-cognition | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-cognition","json":"/api/articles/pt-141-cognition","markdown":"/api/articles/pt-141-cognition/bundle?format=markdown","skill":"/api/articles/pt-141-cognition/skill","topology":"/api/articles/pt-141-cognition/topology","versions":"/api/articles/pt-141-cognition/revisions","invocations":"/api/articles/pt-141-cognition/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-cognition","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"ff18719c741b87a82ed3ee06c561cecdbd36f3638f71f2642d1cce0a67068313","object":{"object_type":"article-object","identity":{"id":"article:pt-141-cognition","slug":"pt-141-cognition","title":"PT-141 for Cognition: Melanocortin Pathways, CNS Arousal, and the Evidence Base"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/pt-141-cognition","role":"explain","audience":"human"},"skill":{"route":"/api/articles/pt-141-cognition/skill","role":"direct behavior","audience":"model","content":"---\nname: pt-141-cognition\ndescription: Apply the PT-141 for Cognition: Melanocortin Pathways, CNS Arousal, and the Evidence Base article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# PT-141 for Cognition: Melanocortin Pathways, CNS Arousal, and the Evidence Base\n\nThis Skill is the behavioral expression of [the canonical article](/a/pt-141-cognition). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/pt-141-cognition.\n- Read claims and relationships at /api/articles/pt-141-cognition/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Cognition depends on coordinated brain networks for motivation, reward processing, attention, and memory consolidation. When these networks underperform, people often notice reduced drive to start tasks, flatter emotion\n\n## Representations\n\n- Human: /a/pt-141-cognition\n- JSON: /api/articles/pt-141-cognition\n- Relationships: /api/articles/pt-141-cognition/topology\n- History: /api/articles/pt-141-cognition/revisions\n"},"json":{"route":"/api/articles/pt-141-cognition","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/pt-141-cognition/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","pt","141","cognition"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/pt-141-cognition/invocations?status=success","failure_events":"/api/articles/pt-141-cognition/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"pt-141-cognition","title":"PT-141 for Cognition: Melanocortin Pathways, CNS Arousal, and the Evidence Base","body":"## What's breaking down\nCognition depends on coordinated brain networks for motivation, reward processing, attention, and memory consolidation. When these networks underperform, people often notice reduced drive to start tasks, flatter emotional tone during focused work, or weaker follow-through on learning. Melanocortin receptors (especially MC3R and MC4R) sit in hypothalamic and limbic areas that help regulate these functions. If signaling through these receptors is low, the excitatory push that normally supports motivated attention and reward-linked memory can weaken. PT-141 is a melanocortin agonist that crosses into central pathways; any discussion of its use for cognition starts from this shared biology rather than from a claim that it repairs structural damage or suppresses symptoms.\n\n## Why PT-141 might help you\n1. If your main issue is low motivational tone or reduced mental arousal when starting cognitively demanding work, PT-141 is discussed because it activates MC4R receptors that have been linked in animal models to increased dopamine release in reward circuits.\n2. If reward sensitivity feels blunted (tasks that used to feel engaging now feel neutral), the same central mechanism that improves sexual desire in human trials could theoretically extend to other appetitive behaviors, though this remains untested in cognition-specific studies.\n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. It acts on central melanocortin pathways rather than on peripheral blood flow or broad neurotransmitter suppression.\n\n## How these fit together\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\nThe single focus here is PT-141 acting on CNS arousal pathways that overlap with motivational aspects of cognition. No additional peptides are in scope, so synergy discussion is limited to how its central mechanism might interact with everyday behaviors that support cognition, such as consistent engagement with learning tasks.\n\n## What the evidence actually shows\nHuman data are confined to sexual desire outcomes. Two identical phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found that 1.75 mg subcutaneous bremelanotide taken as needed produced statistically significant increases in desire scores (FSFI desire domain) and reductions in distress (FSDS-DAO item 13) versus placebo after 24 weeks. These trials enrolled over 1,200 women and reported the effects as clinically meaningful for the sexual endpoint. No cognitive endpoints were measured. Preclinical work shows melanocortin agonists influence sexual behavior and some appetitive responses in rodents, but direct cognition assays (memory, executive function) are absent from published PT-141 studies. Anecdotal reports exist but are low-tier and tied to libido use rather than isolated cognitive testing.\n\n## What scientists say\nResearchers describe PT-141 as a selective melanocortin agonist that acts centrally to modulate excitatory pathways involved in sexual motivation. Reviews note that MC4R signaling can intersect with dopamine systems in the medial preoptic area and limbic regions, providing a mechanistic bridge to reward and drive. Scientists consistently state that any extension to non-sexual cognition is speculative; no dedicated human trials on memory, attention, or executive function have been published. One review highlights that melanocortins broadly influence energy balance, inflammation, and social behavior, yet cautions that receptor subtype distribution and downstream effects vary by brain region and remain incompletely mapped for cognitive domains.\n\n## What people say on Reddit\nUser reports on forums such as r/Biohackers and r/NTNPerformance describe PT-141 primarily in the context of libido and erections. A subset mention secondary feelings of increased well-being, reduced depressive tone, or heightened pleasure during activities, sometimes framed as “antidepressant-like.” These accounts are self-reported, lack controlled conditions or cognitive testing, and often combine PT-141 with other compounds. No consistent reports isolate improvements in focus, memory recall, or problem-solving speed. Tolerance concerns and the need for cycling appear repeatedly in anecdotal threads.\n\n## What people say on X\nPosts on X discussing PT-141 focus almost exclusively on sexual desire and arousal timing. Occasional mentions link the compound to broader “motivation” or “drive,” but these remain tied to libido experiences rather than objective cognitive metrics. No verified high-engagement threads present before-and-after cognitive testing or controlled observations.\n\n## What we do not know\nNo human trials have measured PT-141 effects on standardized cognitive batteries, working memory, processing speed, or attention tasks. It is unknown whether any motivational changes observed in sexual contexts generalize to non-sexual cognitive performance. Long-term effects on brain plasticity or neurodegeneration markers have not been studied. Dose-response relationships for any potential cognitive layer are undefined. Differences between subcutaneous FDA-approved use and research-grade or compounded versions remain uncharacterized for non-sexual outcomes.\n\n## Safety and limits\nThe most common side effects reported in the phase 3 HSDD trials were nausea, flushing, and headache, occurring in 10% or more of participants and leading to discontinuation in a minority. The compound is FDA-approved only for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Off-label exploration for cognition carries the standard risks of any unstudied indication, including unknown interactions and the absence of long-term safety data beyond sexual use. All claims remain graded by available evidence tiers; no cognitive benefit is established in humans.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/pt-141-cognition/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Two phase 3 RCTs showed bremelanotide 1.75 mg SC improved sexual desire scores and reduced distress versus placebo in premenopausal women with HSDD.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the only robust human efficacy data for PT-141; confirms central mechanism but no cognitive endpoints measured.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"PT-141 acts as an agonist at MC3R and MC4R receptors expressed in the central nervous system.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the receptor-level basis for any discussion of CNS effects including possible motivational pathways.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No published human trials have assessed PT-141 on cognitive endpoints such as memory, attention, or executive function.","section":"What we do not know","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies the evidence gap for the article's specific topic.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Anecdotal Reddit reports describe secondary feelings of well-being or pleasure but do not isolate cognitive performance improvements.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents low-tier user observations without controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Phase 3 RCT results showing desire and distress improvements; no cognitive measures.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:18:54.082Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"2e68dd963d3bb9dbc811249c2ee9030d338819fd534e65c496d38645db60f7ed"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/12851303/","title":"PT-141: a melanocortin agonist for the treatment of sexual dysfunction","quote":"PT-141, a synthetic peptide analogue of alpha-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system.","summary":"Mechanism paper confirming receptor targets and CNS expression.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:18:54.082Z","link_status":"ok","quote_status":"verified","prev":"2e68dd963d3bb9dbc811249c2ee9030d338819fd534e65c496d38645db60f7ed","hash":"79f4cee5b28928ac0cb6b51a93bddf771f2dc889e751308b2cc7e5566b16ee36"},{"id":"s3","type":"other","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/","title":"Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder","quote":"The most common side effects of bremelanotide are nausea, vomiting, and flushing.","summary":"Review confirming trial focus remains sexual; no cognition data referenced.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:18:54.082Z","link_status":"ok","quote_status":"unverified","prev":"79f4cee5b28928ac0cb6b51a93bddf771f2dc889e751308b2cc7e5566b16ee36","hash":"f9b242c4b338f755dbcb6e284b5f6d2dcbd4143c8874c86a87d788036a5d2774"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1c39lie/pt_141_for_libido/","title":"PT 141 for libido","quote":"I have an increased sense of well-being, almost zero depression... increased pleasure (hedonic) beyond its effects used for ED.","summary":"User anecdote linking PT-141 to well-being but not to tested cognitive outcomes.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:18:54.082Z","link_status":"ok","quote_status":"unverified","prev":"f9b242c4b338f755dbcb6e284b5f6d2dcbd4143c8874c86a87d788036a5d2774","hash":"cadfae1aef2e6e5bee3467d30fdbe993c4f356d7f18d478dd74b2c993de97327"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:18:54.944Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 for Cognition: Melanocortin Pathways, CNS Arousal, and the Evidence Base","register":"source_ledger","body":"## What's breaking down\nCognition depends on coordinated brain networks for motivation, reward processing, attention, and memory consolidation. When these networks underperform, people often notice reduced drive to start tasks, flatter emotional tone during focused work, or weaker follow-through on learning. Melanocortin receptors (especially MC3R and MC4R) sit in hypothalamic and limbic areas that help regulate these functions. If signaling through these receptors is low, the excitatory push that normally supports motivated attention and reward-linked memory can weaken. PT-141 is a melanocortin agonist that crosses into central pathways; any discussion of its use for cognition starts from this shared biology rather than from a claim that it repairs structural damage or suppresses symptoms.\n\n## Why PT-141 might help you\n1. If your main issue is low motivational tone or reduced mental arousal when starting cognitively demanding work, PT-141 is discussed because it activates MC4R receptors that have been linked in animal models to increased dopamine release in reward circuits.\n2. If reward sensitivity feels blunted (tasks that used to feel engaging now feel neutral), the same central mechanism that improves sexual desire in human trials could theoretically extend to other appetitive behaviors, though this remains untested in cognition-specific studies.\n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. It acts on central melanocortin pathways rather than on peripheral blood flow or broad neurotransmitter suppression.\n\n## How these fit together\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\nThe single focus here is PT-141 acting on CNS arousal pathways that overlap with motivational aspects of cognition. No additional peptides are in scope, so synergy discussion is limited to how its central mechanism might interact with everyday behaviors that support cognition, such as consistent engagement with learning tasks.\n\n## What the evidence actually shows\nHuman data are confined to sexual desire outcomes. Two identical phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found that 1.75 mg subcutaneous bremelanotide taken as needed produced statistically significant increases in desire scores (FSFI desire domain) and reductions in distress (FSDS-DAO item 13) versus placebo after 24 weeks. These trials enrolled over 1,200 women and reported the effects as clinically meaningful for the sexual endpoint. No cognitive endpoints were measured. Preclinical work shows melanocortin agonists influence sexual behavior and some appetitive responses in rodents, but direct cognition assays (memory, executive function) are absent from published PT-141 studies. Anecdotal reports exist but are low-tier and tied to libido use rather than isolated cognitive testing.\n\n## What scientists say\nResearchers describe PT-141 as a selective melanocortin agonist that acts centrally to modulate excitatory pathways involved in sexual motivation. Reviews note that MC4R signaling can intersect with dopamine systems in the medial preoptic area and limbic regions, providing a mechanistic bridge to reward and drive. Scientists consistently state that any extension to non-sexual cognition is speculative; no dedicated human trials on memory, attention, or executive function have been published. One review highlights that melanocortins broadly influence energy balance, inflammation, and social behavior, yet cautions that receptor subtype distribution and downstream effects vary by brain region and remain incompletely mapped for cognitive domains.\n\n## What people say on Reddit\nUser reports on forums such as r/Biohackers and r/NTNPerformance describe PT-141 primarily in the context of libido and erections. A subset mention secondary feelings of increased well-being, reduced depressive tone, or heightened pleasure during activities, sometimes framed as “antidepressant-like.” These accounts are self-reported, lack controlled conditions or cognitive testing, and often combine PT-141 with other compounds. No consistent reports isolate improvements in focus, memory recall, or problem-solving speed. Tolerance concerns and the need for cycling appear repeatedly in anecdotal threads.\n\n## What people say on X\nPosts on X discussing PT-141 focus almost exclusively on sexual desire and arousal timing. Occasional mentions link the compound to broader “motivation” or “drive,” but these remain tied to libido experiences rather than objective cognitive metrics. No verified high-engagement threads present before-and-after cognitive testing or controlled observations.\n\n## What we do not know\nNo human trials have measured PT-141 effects on standardized cognitive batteries, working memory, processing speed, or attention tasks. It is unknown whether any motivational changes observed in sexual contexts generalize to non-sexual cognitive performance. Long-term effects on brain plasticity or neurodegeneration markers have not been studied. Dose-response relationships for any potential cognitive layer are undefined. Differences between subcutaneous FDA-approved use and research-grade or compounded versions remain uncharacterized for non-sexual outcomes.\n\n## Safety and limits\nThe most common side effects reported in the phase 3 HSDD trials were nausea, flushing, and headache, occurring in 10% or more of participants and leading to discontinuation in a minority. The compound is FDA-approved only for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Off-label exploration for cognition carries the standard risks of any unstudied indication, including unknown interactions and the absence of long-term safety data beyond sexual use. All claims remain graded by available evidence tiers; no cognitive benefit is established in humans.","claims":[{"id":"c1","text":"Two phase 3 RCTs showed bremelanotide 1.75 mg SC improved sexual desire scores and reduced distress versus placebo in premenopausal women with HSDD.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the only robust human efficacy data for PT-141; confirms central mechanism but no cognitive endpoints measured.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"PT-141 acts as an agonist at MC3R and MC4R receptors expressed in the central nervous system.","section":"Why PT-141 might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the receptor-level basis for any discussion of CNS effects including possible motivational pathways.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No published human trials have assessed PT-141 on cognitive endpoints such as memory, attention, or executive function.","section":"What we do not know","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies the evidence gap for the article's specific topic.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Anecdotal Reddit reports describe secondary feelings of well-being or pleasure but do not isolate cognitive performance improvements.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents low-tier user observations without controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:18:54.493Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/12851303/","title":"PT-141: a melanocortin agonist for the treatment of sexual dysfunction","quote":"PT-141, a synthetic peptide analogue of alpha-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"other","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/","title":"Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder","quote":"The most common side effects of bremelanotide are nausea, vomiting, and flushing.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1c39lie/pt_141_for_libido/","title":"PT 141 for libido","quote":"I have an increased sense of well-being, almost zero depression... increased pleasure (hedonic) beyond its effects used for ED.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":15336,"tokens_out":3041,"cost":0.0267725,"prev_hash":"genesis","hash":"d5431a8e06f74a723b0250cce9c7b2f1e9af06d8043ea597f9e1e57c8f2f4c20"}],"provenance":[{"ts":"2026-06-30T01:18:54.944Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Cognition\nSlug: pt-141-cognition\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from pepti","response":"{\n  \"slug\": \"pt-141-cognition\",\n  \"title\": \"PT-141 for Cognition: Melanocortin Pathways, CNS Arousal, and the Evidence Base\",\n  \"body\": \"## What's breaking down\\nCognition depends on coordinated brain networks for motivation, reward processing, attention, and memory consolidation. When these networks underperform, people often notice reduced drive to start tasks, flatter emotional tone during focused work, or weaker follow-through on learning. Melanocortin receptors (especially MC3R and MC4R) sit in hypothalamic and limbic areas that help regulate these functions. If signaling through these receptors is low, the excitatory push that normally supports motivated attention and reward-linked memory can weaken. PT-141 is a melanocortin agonist that crosses into central pathways; any discussion of its use for cognition starts from this shared biology rather than from a claim that it repairs structural damage or suppresses symptoms.\\n\\n## Why PT-141 might help you\\n1. If your main issue is low motivational tone or reduced mental arousal when starting cognitively demanding work, PT-141 is discussed because it activates MC4R receptors that have been linked in animal models to increased dopamine release in reward circuits.\\n2. If reward sensitivity feels blunted (tasks that used to feel engaging now feel neutral), the same central mechanism that improves sexual desire in human trials could theoretically extend to other appetitive behaviors, though this remains untested in cognition-specific studies.\\n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. It acts on central melanocortin pathways rather than on peripheral blood flow or broad neurotransmitter suppression.\\n\\n## How these fit together\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\\nThe single","tokens_in":15336,"tokens_out":3041,"cost":0,"prev":"genesis","hash":"e11d402e2e64b5f9ee9aa02e01e4e3f08c763237c75967983523562e425ed068"},{"ts":"2026-07-17T02:41:04.978Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-cognition","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e11d402e2e64b5f9ee9aa02e01e4e3f08c763237c75967983523562e425ed068","hash":"a3e590b81a96aafbda5af36d20861058cea309ec1da2745fd9c976340b908905"}],"energy":{"passes":2,"tokens_in":15336,"tokens_out":3041,"tokens_total":18377,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"a3e590b81a96aafbda5af36d20861058cea309ec1da2745fd9c976340b908905"},"posted_at":"2026-06-29T21:32:52.033Z","created_at":"2026-06-29T21:32:52.033Z","updated_at":"2026-07-17T02:41:04.978Z","machine":{"shape":"article.machine/v1","slug":"pt-141-cognition","kind":"article","read":{"human":"https://miscsubjects.com/a/pt-141-cognition","json":"https://miscsubjects.com/api/articles/pt-141-cognition","bundle":"https://miscsubjects.com/api/articles/pt-141-cognition/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/pt-141-cognition/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=pt-141-cognition","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-cognition\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"pt-141-cognition\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/pt-141-cognition/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"pt-141-cognition\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/pt-141-cognition | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/pt-141-cognition","json":"/api/articles/pt-141-cognition","markdown":"/api/articles/pt-141-cognition/bundle?format=markdown","skill":"/api/articles/pt-141-cognition/skill","topology":"/api/articles/pt-141-cognition/topology","versions":"/api/articles/pt-141-cognition/revisions","invocations":"/api/articles/pt-141-cognition/invocations"},"editorial_review":null,"editorial_audit":{"slug":"pt-141-cognition","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"ff18719c741b87a82ed3ee06c561cecdbd36f3638f71f2642d1cce0a67068313"}}}